Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Expected to Earn Q1 2023 Earnings of ($0.03) Per Share

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTXGet Rating) – Analysts at HC Wainwright issued their Q1 2023 earnings estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Friday, March 10th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.03) per share for the quarter. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ FY2027 earnings at ($0.01) EPS.

Lineage Cell Therapeutics Price Performance

Lineage Cell Therapeutics stock opened at $1.43 on Monday. The stock has a market capitalization of $243.07 million, a price-to-earnings ratio of -9.53 and a beta of 1.66. Lineage Cell Therapeutics has a 1 year low of $1.02 and a 1 year high of $1.79.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LCTX. Laurion Capital Management LP purchased a new position in Lineage Cell Therapeutics during the 2nd quarter worth $3,827,000. Millennium Management LLC increased its holdings in Lineage Cell Therapeutics by 471.7% during the 2nd quarter. Millennium Management LLC now owns 1,020,446 shares of the company’s stock worth $1,612,000 after purchasing an additional 841,953 shares during the period. JPMorgan Chase & Co. increased its holdings in Lineage Cell Therapeutics by 44.1% during the 1st quarter. JPMorgan Chase & Co. now owns 1,849,662 shares of the company’s stock worth $2,849,000 after purchasing an additional 566,385 shares during the period. Citigroup Inc. boosted its position in Lineage Cell Therapeutics by 250.9% during the 4th quarter. Citigroup Inc. now owns 477,174 shares of the company’s stock valued at $558,000 after acquiring an additional 341,193 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Lineage Cell Therapeutics during the 3rd quarter valued at $291,000. 38.11% of the stock is currently owned by hedge funds and other institutional investors.

Lineage Cell Therapeutics Company Profile

(Get Rating)

Lineage Cell Therapeutics, Inc operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company’s programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery.

Read More

Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with's FREE daily email newsletter.